A new stem cell-derived system for screening experimental drugs for cardiotoxicity could identify dangerous side effects early in the development process, thereby potentially saving time, lives and money. Cardiotoxicity is one of the primary reasons new drugs wash out in preclinical or even full clinical trials. Currently used assays are ineffective at assessing potential adverse interactions with other biochemical or contractile processes.